Version 1
: Received: 26 August 2024 / Approved: 27 August 2024 / Online: 27 August 2024 (11:20:59 CEST)
Version 2
: Received: 27 August 2024 / Approved: 28 August 2024 / Online: 28 August 2024 (10:45:50 CEST)
How to cite:
Asiri, A.; Al Qarni, A. A.; Bakillah, A. The Interlinking Metabolic Association between Type 2 Diabetes and Cancer: Molecular Mechanisms and Therapeutic Insights. Preprints2024, 2024081919. https://doi.org/10.20944/preprints202408.1919.v2
Asiri, A.; Al Qarni, A. A.; Bakillah, A. The Interlinking Metabolic Association between Type 2 Diabetes and Cancer: Molecular Mechanisms and Therapeutic Insights. Preprints 2024, 2024081919. https://doi.org/10.20944/preprints202408.1919.v2
Asiri, A.; Al Qarni, A. A.; Bakillah, A. The Interlinking Metabolic Association between Type 2 Diabetes and Cancer: Molecular Mechanisms and Therapeutic Insights. Preprints2024, 2024081919. https://doi.org/10.20944/preprints202408.1919.v2
APA Style
Asiri, A., Al Qarni, A. A., & Bakillah, A. (2024). The Interlinking Metabolic Association between Type 2 Diabetes and Cancer: Molecular Mechanisms and Therapeutic Insights. Preprints. https://doi.org/10.20944/preprints202408.1919.v2
Chicago/Turabian Style
Asiri, A., Ali Ahmed Al Qarni and Ahmed Bakillah. 2024 "The Interlinking Metabolic Association between Type 2 Diabetes and Cancer: Molecular Mechanisms and Therapeutic Insights" Preprints. https://doi.org/10.20944/preprints202408.1919.v2
Abstract
Type 2 Diabetes mellitus (T2DM) and cancer share common risk factors including obesity, in-flammation, hyperglycemia, and hyperinsulinemia. High insulin levels activate PI3K/Akt/mTOR signaling pathway promoting cancer cell growth, survival, proliferation, metastasis, and an-ti-apoptosis. The inhibition of PI3K/Akt/mTOR signaling pathway for cancer remains a promising therapy, however, the combination of therapeutic inhibitors may solve the resistance to such agents. Understanding the metabolic link between diabetes and cancer can assist in improving the therapeutic strategies used for the management of cancer patients with diabetes and vice versa. This review provides an overview of shared molecular mechanisms between diabetes and cancer as well as discusses established and emerging therapeutic anti-cancer agents targeting the PI3K/Akt/mTOR pathway in cancer management.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
